1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical prepartions comprising them
申请人:Aventis Pharma Deutschland GmbH
公开号:US20020077344A1
公开(公告)日:2002-06-20
The invention relates to novel 1-(p-thienylbenzyl)imidazoles of formula (I)
1
where the radicals R(1) to R(6), X, and Y have the meaning indicated in the description, which are potent agonists of angiotensin (1-7) receptors and owing to the production and release of the vasorelaxant, antithrombotic, and cardioprotective messengers cyclic 3′,5′-guanosine monophosphate (cGMP) and nitrogen monoxide (NO) associated with the stimulation of these receptors on endothelial cells are valuable pharmaceuticals for the treatment and prophylaxis of high blood pressure, cardiac hypertrophy, cardiac insufficiency, coronary heart diseases such as angina pectoris, cardiac infarct, vascular restenosis after angioplasty, cardiomyopathies, endothelial dysfunction or endothelial damage, e.g., as a result of arteriosclerotic processes or diabetes mellitus, and also of arterial and venous thromboses.
本发明涉及一种新的1-(p-噻吩基苯基)咪唑类化合物,其化学式为(I),其中基团R(1)到R(6)、X和Y的含义如说明书中所示。这些化合物是血管紧张素(1-7)受体的强效激动剂,并由于刺激内皮细胞上这些受体产生和释放血管舒张剂、抗血栓和心脏保护信使环磷酸鸟苷单磷酸(cGMP)和一氧化氮(NO),因此对于治疗和预防高血压、心肌肥大、心力衰竭、冠心病如心绞痛、心肌梗死、血管成形术后的血管再狭窄、心肌病、内皮功能障碍或内皮损伤,如动脉硬化过程或糖尿病所致的,以及动脉和静脉血栓等方面具有重要的药物价值。